Tysabri Out Of Remission; Returns With Updated Indication, Risk Management
Executive Summary
The indication for Biogen Idec/Elan's re-approved multiple sclerosis therapy Tysabri (natalizumab) stops short of limiting it to use as a second-line therapy
You may also be interested in...
CDER’s Neurology Division Prepares For New Leadership With Director Katz’s Retirement
Russell Katz will retire following a 30-year career at FDA; his departure comes as the agency is embarking on new efforts to encourage drug development for Alzheimer’s disease and amyotrophic lateral sclerosis.
Tysabri Risk Communication Goes Beyond REMS With Monthly Update For Docs
Biogen Idec's decision to start providing doctors with monthly updates on progressive multifocal leukoencephalopathy cases among Tysabri patients shows the firm's confidence that providing additional risk information will not discourage use of the product
Tysabri Risk Communication Goes Beyond REMS With Monthly Update For Docs
Biogen Idec's decision to start providing doctors with monthly updates on progressive multifocal leukoencephalopathy cases among Tysabri patients shows the firm's confidence that providing additional risk information will not discourage use of the product